DOCSLIB.ORG

Clear Choices in Managing Epidermal Tinea Infections

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clear Choices in Managing Epidermal Tinea Infections Applied Evidence N EW R ESEARCH F INDINGS T HAT A RE C HANGING C LINICAL P RACTICE Clear choices in managing epidermal tinea infections Brian Thomas, MD Medical Department, Commander Naval Coastal Warfare Group One Practice recommendations hough findings on history and physical examination are sometimes sufficient to ■ Potassium hydroxide preparation should T make a diagnosis of tinea infection, a be used as an aid to diagnosis for all potassium hydroxide (KOH) study usually is erythrosquamous lesions (B). required for confirmation. Even the KOH study ■ Fungal culture should be used in cases can be misleading, however, if a patient recently in which history, physical examination, and self-administered a topical antifungal agent. This potassium hydroxide preparation fail to article describes the varying appearance of tinea clearly exclude a diagnosis of tinea (B). infections according to their anatomic location, and outlines a careful work-up. ■ Short-duration topical therapy with Highly effective and affordable over-the- terbinafine, naftifine, and butenafine counter medications have proliferated, and is efficacious for most epidermal tinea short-course therapy is available. Based on infections (A). systematic reviews of randomized, controlled ■ Oral antifungal agents are important studies, it is possible to recommend specific in the treatment of tinea infections that first-line therapies for tinea infections. are widespread, fail to respond to topical treatment, involve the thick stratum ■ MANIFESTATIONS corneum of the soles and palms, or OF TINEA INFECTION occur in immunosuppressed patients. Clinical manifestations of tinea vary with anatomic ■ Short courses of oral itraconazole and location, duration of infection, and pathogen terbinafine are safe and effective in (see page 856). In general, zoophilic dermato- treating tinea infections (A). phytes evoke a more vigorous host response than the anthropophilic species.5 Shared features of many dermatophyte infections include erythema, scaling, pruritus, ring formation, and central clearing of lesions. Table 1 reviews published data on the diagnostic value of selected clinical signs in suspected tinea infection.6 Tinea pedis Correspondence: Brian Thomas, MD, NOLF-IB, Bldg 184, Box 357140, San Diego, Ca 92135. E-mail: Tinea of the foot may manifest as interdigital, [email protected]. plantar, or acute vesicular disease. Toe webs 850 NOVEMBER 2003 / VOL 52, NO 11 · The Journal of Family Practice MANAGING EPIDERMAL TINEA INFECTIONS AppliTABLE 1 Diagnostic value of selected signs and symptoms in tinea infection Sign/symptom Sensitivity Specificity PV+ PV– LR+ LR– Scaling 77% 20% 17% 80% 0.96 1.15 Erythema 69% 31% 18% 83% 1.00 1.00 Pruritus 54% 40% 16% 80% 0.90 1.15 Central clearing 42% 65% 20% 84% 1.20 0.89 Concentric rings 27% 80% 23% 84% 1.35 0.91 Maceration 27% 84% 26% 84% 1.69 0.87 Note: Signs and symptoms were compiled by 27 general practitioners prior to submission of skin for fungal culture. Specimens were taken from 148 consecutive patients with erythematosquamous lesions of glabrous skin. Culture results were considered the gold standard. PV+, positive predictive value; PV–, negative predictive value; LR+, positive likelihood ratio; LR–, negative likelihood ratio. Adapted from Lousbergh et al, Fam Pract 1999; 16:611–615.6 Level of evidence=2b. For an explanation of levels of evidence, see page 865. and soles of the feet are the sites most erythrasma by lack of bright coral appearance commonly affected. Tinea pedis occurs most when examined with a Wood’s lamp. Tinea pedis commonly in postpubertal adolescents and infections also lack the well-demarcated erosions, adults, but may be seen in children.7 or pits, of pitted keratolysis. Evidence of concur- With interdigital infection, toe webs may rent onychomycosis should increase the suspicion become scaly, pruritic, and fissured. Interaction that tinea pedis is the correct diagnosis. of bacteria and infecting dermatophytes may lead to a white, soggy maceration.8 Extension Tinea manuum from the web space to the dorsal or plantar Tinea of the hand is usually analogous to surface commonly occurs. moccasin-type tinea pedis. The palm appears In chronic plantar or moccasin-type tinea hyperkeratotic and has very fine white scale pedis, the entire surface of the sole may be that emphasizes the normal lines of the hand. covered with fine, white scale and may assume Tinea of the dorsal surface of the hand usually a hyperkeratotic appearance. Chronic web infec- occurs in the classic ringworm pattern. Tinea tion may lead to acute inflammation character- manuum is often seen in association with tinea ized by vesicles, pustules, and bullae over the pedis and onychomycosis. Many clinicians are sole or the dorsum of the foot.5 familiar with the “one hand, two feet” syndrome, Differential diagnosis. The differential diag- in which the palmar surfaces of both feet nosis includes dry skin, pitted keratolysis, and one hand are infected (Figure 1).9 erythrasma, and contact dermatitis. Some Onychomycosis often occurs in association with conditions may appear very similar to tinea this presentation of tinea. pedis, increasing the importance of KOH prep Differential diagnosis. The pattern of tinea and fungal culture. manuum may be confused with those of eczema, Tinea pedis may be distinguished from contact dermatitis, palmar psoriasis, or even NOVEMBER 2003 / VOL 52, NO 11 · The Journal of Family Practice 851 MANAGING EPIDERMAL TINEA INFECTIONS FIGURE 1 Tinea pedis FIGURE 2 Tinea corporis The common “1 hand, 2 feet” syndrome of tinea pedis. Widespread tinea corporis. This patient would not be a This syndrome usually requires systemic therapy. candidate for topical treatment. normal, rough hands. Unilateral involvement, ly develop a raised border and begin to spread presence of fingernail onychomycosis, lack of his- radially. As the ring expands, the central portion tory indicating irritant or allergen exposure, and of the lesion often clears. This pattern leads to the absence of psoriatic nail changes should increase formation of irregular circles that gives tinea cor- the suspicion of palmar tinea manuum. poris its common name, ringworm (Figure 2). Tinea faciale is less common, but generally Tinea cruris has a similar appearance with central clearing Tinea of the groin is most common in adult males of lesions. Tinea faciale may not always exhibit and is promoted by a warm, moist environment. the sharply demarcated border of tinea corporis. Tinea cruris begins in the crural fold and spreads Differential diagnosis. Eczema, impetigo, onto the thigh. The interior portion of the lesion is early pityriasis rosea, and localized psoriasis usually erythematous or slightly brown in light- can mimic tinea corporis. History of exposure to skinned individuals. The leading edge often persons or animals (typically house pets) with advances in a sharply demarcated semicircle with known ringworm should increase suspicion of a raised, slightly scaling border. The lesion is tinea corporis. Current or past evidence of most often bilateral, sparing the skin of the scro- psoriasis or eczema should broaden the differ- tum. Pruritus is common and increases as sweat ential to include atypical presentations of these macerates the irritated skin. diseases. Differential diagnosis. Candidiasis, intertri- go, and erythrasma can cause similar lesions. It ■ DIAGNOSING TINEA: HISTORY is helpful to recall that candidiasis may involve AND EXAM NOT ENOUGH the scrotum and penis while tinea cruris does so In some cases, findings on history and physical rarely. An additional helpful feature is the char- evaluation are so characteristic of tinea that acteristic bright coral appearance of erythrasma they alone may allow the clinician to make a when examined with a Wood’s lamp, absent in firm diagnosis. However, studies have shown cases of tinea cruris. that relying upon history and physical examina- tion may result in a many missed diagnoses.6 Tinea corporis and tinea faciale Accordingly, consider tinea in all instances of Tinea infections of the face and body begin as flat, papulosquamous skin disease and follow up scaly, and often pruritic macules that subsequent- appropriately. Figure 3 presents a simple 852 NOVEMBER 2003 / VOL 52, NO 11 · The Journal of Family Practice MANAGING EPIDERMAL TINEA INFECTIONS FIGURE 3 Evaluating possible tinea infection of the skin Patient's history and findings on physical exam suggest tinea infection. Treat with oral terbinafine or itraconazole. One week of therapy may suffice. Prepare KOH slide for (See text for details.) microscopic evaluation. YES Does microscopic exam reveal YES Is infection widespread or recurrent over palmar fungal hyphae typical of tinea? or plantar surfaces? Or is the patient immunosuppressed? NO NO YES Be sure the patient has not self-med- icated with an OTC antifungal agent. YES Arrange for fungal culture. Treat with topical Is your clinical suspicion terbinafine, naftifine, of tinea high? Is the result butenafine, or an azole positive? agent. (Terbinafine has NO proven superior to azoles and is available as inex- NO pensive OTC formulation.) If topical treatment fails to Consider alternative diagnoses yield acceptable clinical Fungal culture is highly (see text for details of differential). response, consider oral specific. Consider alterna- If treatment is unsuccessful, consider antifungal regimen tive diagnoses (see text for repeating KOH prep and arranging details of differential). for fungal culture. algorithm
Load more

Recommended publications
  • 35 Cyproterone Acetate and Ethinyl Estradiol Tablets 2 Mg/0
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrCYESTRA®-35 cyproterone acetate and ethinyl estradiol tablets 2 mg/0.035 mg THERAPEUTIC CLASSIFICATION Acne Therapy Paladin Labs Inc. Date of Preparation: 100 Alexis Nihon Blvd, Suite 600 January 17, 2019 St-Laurent, Quebec H4M 2P2 Version: 6.0 Control # 223341 _____________________________________________________________________________________________ CYESTRA-35 Product Monograph Page 1 of 48 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................................. 3 INDICATION AND CLINICAL USE ..................................................................................................... 3 CONTRAINDICATIONS ........................................................................................................................ 3 WARNINGS AND PRECAUTIONS ....................................................................................................... 4 ADVERSE REACTIONS ....................................................................................................................... 13 DRUG INTERACTIONS ....................................................................................................................... 16 DOSAGE AND ADMINISTRATION ................................................................................................ 20 OVERDOSAGE ....................................................................................................................................
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Transport of Dangerous Goods
    ST/SG/AC.10/1/Rev.16 (Vol.I) Recommendations on the TRANSPORT OF DANGEROUS GOODS Model Regulations Volume I Sixteenth revised edition UNITED NATIONS New York and Geneva, 2009 NOTE The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. ST/SG/AC.10/1/Rev.16 (Vol.I) Copyright © United Nations, 2009 All rights reserved. No part of this publication may, for sales purposes, be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying or otherwise, without prior permission in writing from the United Nations. UNITED NATIONS Sales No. E.09.VIII.2 ISBN 978-92-1-139136-7 (complete set of two volumes) ISSN 1014-5753 Volumes I and II not to be sold separately FOREWORD The Recommendations on the Transport of Dangerous Goods are addressed to governments and to the international organizations concerned with safety in the transport of dangerous goods. The first version, prepared by the United Nations Economic and Social Council's Committee of Experts on the Transport of Dangerous Goods, was published in 1956 (ST/ECA/43-E/CN.2/170). In response to developments in technology and the changing needs of users, they have been regularly amended and updated at succeeding sessions of the Committee of Experts pursuant to Resolution 645 G (XXIII) of 26 April 1957 of the Economic and Social Council and subsequent resolutions.
    [Show full text]
  • Problématiques Environnementales Et Du Développement Durable
    Université Paris EST Ecole Doctorale Sciences, Ingénierie et Environnement THESE DE DOCTORAT Présentée par: SEYDINA IBRAHIMA KEBE Pour obtenir le grade de Docteur de l’Université Paris EST Spécialité : Chimie et Sciences des Matériaux Sujet de Thèse : Synthèse de matériaux monolithiques pour la séparation et la catalyse en phase liquide: Problématiques environnementales et du développement durable Soutenance le 9 décembre 2016 Devant la commission d’examen formée de : K. Faure : Chargée de recherche, CNRS Rapporteur T. Tran-Maignan : Maître de conférences Rapporteur F. Le Derf : Professeur Examinateur A. Elaissari : Directeur de recherche, CNRS Examinateur A. Bressy : Chargée de recherche, CNRS Membre invité M. Guerrouache : Ingénieur de recherche Membre invité B. Carbonnier : Professeur Directeur de thèse Thèse réalisée au sein de l’équipe Systèmes Polymères Complexes, ICMPE, CNRS, Thiais France Remerciements Je tiens à profiter de ce rapport pour exprimer mes plus grands et chaleureux remerciements envers tous ceux qui ont, en leur manière, contribué à la réussite de cette thèse Cette thèse a pu être réalisée grâce à l'accueil Madame Valérie LANGLOIS adjointe directrice de l’ICMPE, directrice du SPC professeur et chercheuse à l’Université Paris Est Créteil (UPEC). Je lui témoigne ma reconnaissance. Je n’aurais jamais commencé sans exprimer tout particulièrement mes plus grands remerciements et à témoigner toute ma reconnaissance à Benjamin CARBONNIER mon directeur de thèse, professeur des universités à l’UPEC pour l’expérience enrichissante qu’il m’a fait vivre. De simples mots, ne sauraient décrire ma satisfaction à son égard. Je tiens à remercier Mohamed GUERROUACHE, ingénieur, pour son temps consacré à me donner des explications et à me guider.
    [Show full text]
  • Clotrimazole Loaded Ufosomes for Topical Delivery: Formulation Development and In-Vitro Studies
    molecules Article Clotrimazole Loaded Ufosomes for Topical Delivery: Formulation Development and In-Vitro Studies Pradeep Kumar Bolla 1 , Carlos A. Meraz 1, Victor A. Rodriguez 1, Isaac Deaguero 1, Mahima Singh 2 , Venkata Kashyap Yellepeddi 3,4 and Jwala Renukuntla 5,* 1 Department of Biomedical Engineering, College of Engineering, The University of Texas at El Paso, 500 W University Ave, El Paso, TX 79968, USA 2 Department of Pharmaceutical Sciences, University of the Sciences in Philadelphia, Philadelphia, PA 19104, USA 3 Division of Clinical Pharmacology, Department of Pediatrics, University of Utah, Salt Lake City, UT 84112, USA 4 Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA 5 Department of Basic Pharmaceutical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, NC 27240, USA * Correspondence: [email protected] Received: 9 August 2019; Accepted: 28 August 2019; Published: 29 August 2019 Abstract: Global incidence of superficial fungal infections caused by dermatophytes is high and affects around 40 million people. It is the fourth most common cause of infection. Clotrimazole, a broad spectrum imidazole antifungal agent is widely used to treat fungal infections. Conventional topical formulations of clotrimazole are intended to treat infections by effective penetration of drugs into the stratum corneum. However, drawbacks such as poor dermal bioavailability, poor penetration, and variable drug levels limit the efficiency. The present study aims to load clotrimazole into ufosomes and evaluate its topical bioavailability. Clotrimazole loaded ufosomes were prepared using cholesterol and sodium oleate by thin film hydration technique and evaluated for size, polydispersity index, and entrapment efficiency to obtain optimized formulation.
    [Show full text]
  • TRP Mediation
    molecules Review Remedia Sternutatoria over the Centuries: TRP Mediation Lujain Aloum 1 , Eman Alefishat 1,2,3 , Janah Shaya 4 and Georg A. Petroianu 1,* 1 Department of Pharmacology, College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi 127788, United Arab Emirates; [email protected] (L.A.); Eman.alefi[email protected] (E.A.) 2 Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi 127788, United Arab Emirates 3 Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, The University of Jordan, Amman 11941, Jordan 4 Pre-Medicine Bridge Program, College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi 127788, United Arab Emirates; [email protected] * Correspondence: [email protected]; Tel.: +971-50-413-4525 Abstract: Sneezing (sternutatio) is a poorly understood polysynaptic physiologic reflex phenomenon. Sneezing has exerted a strange fascination on humans throughout history, and induced sneezing was widely used by physicians for therapeutic purposes, on the assumption that sneezing eliminates noxious factors from the body, mainly from the head. The present contribution examines the various mixtures used for inducing sneezes (remedia sternutatoria) over the centuries. The majority of the constituents of the sneeze-inducing remedies are modulators of transient receptor potential (TRP) channels. The TRP channel superfamily consists of large heterogeneous groups of channels that play numerous physiological roles such as thermosensation, chemosensation, osmosensation and mechanosensation. Sneezing is associated with the activation of the wasabi receptor, (TRPA1), typical ligand is allyl isothiocyanate and the hot chili pepper receptor, (TRPV1), typical agonist is capsaicin, in the vagal sensory nerve terminals, activated by noxious stimulants.
    [Show full text]
  • Molecular Analysis of Dermatophytes Suggests Spread of Infection Among Household Members
    Molecular Analysis of Dermatophytes Suggests Spread of Infection Among Household Members Mahmoud A. Ghannoum, PhD; Pranab K. Mukherjee, PhD; Erin M. Warshaw, MD; Scott Evans, PhD; Neil J. Korman, MD, PhD; Amir Tavakkol, PhD, DipBact Practice Points When a patient presents with tinea pedis or onychomycosis, inquire if other household members also have the infection, investigate if they have a history of concomitant tinea pedis and onychomycosis, and examine for plantar scaling and/or nail discoloration. If the variables above areCUTIS observed, think about spread of infection and treatment options. Dermatophyte infection from the same strains may Drs. Ghannoum, Mukherjee, and Korman are from University be an important route for transmission of derma- Hospitals Case Medical Center, Cleveland, Ohio. Dr. Warshaw is from the University of Minnesota, Minneapolis, and Minneapolis Veterans tophytoses within a household. In this study, we AffairsDo Medical Center. Dr. Evans is from Notthe Harvard School of Public used molecularCopy methods to identify dermatophytes Health, Boston, Massachusetts. Dr. Tavakkol was from Novartis in members of dermatophyte-infected households Pharmaceuticals Corporation, East Hanover, New Jersey, and and evaluated variables associated with the currently is from Topica Pharmaceuticals, Inc, Los Altos, California. spread of infection. Fungal species were identi- This article was supported by a grant from Novartis Pharmaceuticals Corporation. Dr. Ghannoum has served as a consultant and/or fied by polymerase chain reaction (PCR) using speaker for and has received grants and contracts from Merck & Co, primers targeting the internal transcribed spacer Inc; Novartis Pharmaceuticals Corporation; Pfizer Inc; and Stiefel, (ITS) regions (ITS1 and ITS4). For strain differen- a GSK company.
    [Show full text]
  • Dermatophyte and Non-Dermatophyte Onychomycosis in Singapore
    Australas J. Dermatol 1992; 33: 159-163 DERMATOPHYTE AND NON-DERMATOPHYTE ONYCHOMYCOSIS IN SINGAPORE JOYCE TENG-EE LIM, HOCK CHENG CHUA AND CHEE LEOK GOH Singapore SUMMARY Onychomycosis is caused by dermatophytes, moulds and yeasts. It is important to identify the non-dermatophyte moulds as they are resistant to the usual anti-fungals. A prospective study was undertaken in the National Skin Centre, Singapore to study the pattern of dermatophyte and non-dermatophyte onychomycosis. 53 male and 47 female patients seen between June 1990 and June 1991 were entered into the study. Direct microscopy was done and the nail clippings were cultured. Toe and finger nails were equally infected. Dermatophytes were isolated from 21 patients namely, T. rubrum (12/21), T. interdigitale (5/21), T. mentagrophytes (3/21) and T. violaceum (1/21). Candida onychomycosis occurred in 39 patients and was caused by C. albicans (38/39) and C. parapsilosis (1/39). 37/39 patients had associated paronychia. 5 types of moulds were isolated from 12 patients, namely Fusarium species (6/12), Aspergillus species (3/12), S. brevicaulis (1/12), Aureobasilium species (1/12) and Penicillium species (1/12). Although the clinical pattern and microscopy may predict the type of organisms, in practice this is difficult. Only cultures were confirmatory. 28% (28/100) had negative cultures despite a positive microscopy, and moulds (12/100) grown might be contaminants rather than pathogens. Key words: Moulds, yeasts, fungi, tinea, onychomycosis, dermatophyte, non-dermatophyte INTRODUCTION METHODS AND MATERIALS Onychomycosis, a common nail disorder, is 100 consecutive patients, seen in our centre caused by dermatophytes, non-dermatophyte between June 1990 and June 1991, with a new moulds, or yeasts.
    [Show full text]
  • Step Therapy Criteria Drug Class Topical Antifungal Agents (Brand Products Only)
    STEP THERAPY CRITERIA DRUG CLASS TOPICAL ANTIFUNGAL AGENTS (BRAND PRODUCTS ONLY) BRAND NAME (generic) ECOZA (econazole) ERTACZO (sertaconazole) EXELDERM (sulconazole nitrate) LOPROX (ciclopirox shampoo) LOTRISONE (clotrimazole/betamethasone) LUZU (luliconazole) MENTAX (butenafine) NAFTIN (naftifine) OXISTAT (oxiconazole) VUSION (miconazole/zinc oxide/white petrolatum) XOLEGEL (ketoconazole) Antifungal Topical Step Therapy Policy 06-2017 CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members. CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst of Maryland, Inc., Group Hospitalization and Medical Services, Inc., CareFirst BlueChoice, Inc., The Dental Network and First Care, Inc. are independent licensees of the Blue Cross and Blue Shield Association. In the District of Columbia and Maryland, CareFirst MedPlus is the business name of First Care, Inc. In Virginia, CareFirst MedPlus is the business name of First Care, Inc. of Maryland (used in VA by: First Care, Inc.). ® Registered trademark of the Blue Cross and Blue Shield Association Page 1 of 4 Status: CVS Caremark Criteria Type: Initial Step Therapy; Post Step Therapy Prior Authorization POLICY FDA-APPROVED INDICATIONS Ecoza Ecoza topical 1% foam is indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton
    [Show full text]
  • Managing Athlete's Foot
    South African Family Practice 2018; 60(5):37-41 S Afr Fam Pract Open Access article distributed under the terms of the ISSN 2078-6190 EISSN 2078-6204 Creative Commons License [CC BY-NC-ND 4.0] © 2018 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0 REVIEW Managing athlete’s foot Nkatoko Freddy Makola,1 Nicholus Malesela Magongwa,1 Boikgantsho Matsaung,1 Gustav Schellack,2 Natalie Schellack3 1 Academic interns, School of Pharmacy, Sefako Makgatho Health Sciences University 2 Clinical research professional, pharmaceutical industry 3 Professor, School of Pharmacy, Sefako Makgatho Health Sciences University *Corresponding author, email: [email protected] Abstract This article is aimed at providing a succinct overview of the condition tinea pedis, commonly referred to as athlete’s foot. Tinea pedis is a very common fungal infection that affects a significantly large number of people globally. The presentation of tinea pedis can vary based on the different clinical forms of the condition. The symptoms of tinea pedis may range from asymptomatic, to mild- to-severe forms of pain, itchiness, difficulty walking and other debilitating symptoms. There is a range of precautionary measures available to prevent infection, and both oral and topical drugs can be used for treating tinea pedis. This article briefly highlights what athlete’s foot is, the different causes and how they present, the prevalence of the condition, the variety of diagnostic methods available, and the pharmacological and non-pharmacological management of the
    [Show full text]
  • Therapeutic Class Overview Antifungals, Topical
    Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to
    [Show full text]
  • Red-Brown Patches in the Groin
    DERMATOPATHOLOGY DIAGNOSIS Red-Brown Patches in the Groin Dong Chen, MD, PhD; Tammie C. Ferringer, MD Eligible for 1 MOC SA Credit From the ABD This Dermatopathology Diagnosis article in our print edition is eligible for 1 self-assessment credit for Maintenance of Certification from the American Board of Dermatology (ABD). After completing this activity, diplomates can visit the ABD website (http://www.abderm.org) to self-report the credits under the activity title “Cutis Dermatopathology Diagnosis.” You may report the credit after each activity is completed or after accumu- lating multiple credits. A 66-year-old man presented with reddish arciform patchescopy in the inguinal area. THE BEST DIAGNOSIS IS: a. candidiasis b. noterythrasma c. pitted keratolysis d. tinea cruris Doe. tinea versicolor H&E, original magnification ×600. PLEASE TURN TO PAGE 419 FOR THE DIAGNOSIS CUTIS Dr. Chen is from the Department of Pathology and Anatomical Sciences, University of Missouri, Columbia. Dr. Ferringer is from the Departments of Dermatology and Laboratory Medicine, Geisinger Medical Center, Danville, Pennsylvania. The authors report no conflict of interest. Correspondence: Dong Chen, MD, PhD, Department of Pathology and Anatomical Sciences, University of Missouri, One Hospital Dr, MA204, DC018.00, Columbia, MO 65212 ([email protected]). 416 I CUTIS® WWW.MDEDGE.COM/CUTIS Copyright Cutis 2018. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher. DERMATOPATHOLOGY DIAGNOSIS DISCUSSION THE DIAGNOSIS: Erythrasma rythrasma usually involves intertriginous areas surface (Figure 1) compared to dermatophyte hyphae that (eg, axillae, groin, inframammary area). Patients tend to be parallel to the surface.2 E present with well-demarcated, minimally scaly, red- Pitted keratolysis is a superficial bacterial infection brown patches.
    [Show full text]